Beranda › Kanker Tiroid › Texas
Uji klinis Kanker Tiroid di Texas
15 studi untuk Kanker Tiroid mencari peserta di lokasi di Texas.
Kota di Texas
Teks studi resmi (Bahasa Inggris)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- The Don and Sybil Harrington Cancer Center, Amarillo
- UT MD Anderson Cancer Center, Houston
- Audie L Murphy VA Hospital, San Antonio
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069DESTINY-PANTUMOUR04
- Research Site, Dallas
Menerima pesertaStudi observasional
Usia 18 hingga 130 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07124000Global Real World Data in Patients With Advanced Thyroid Cancer on Standard of Care and Specialized Interventions- Registry of Oncologic Outcomes With Testing and Treatment.
- MD Anderson Cancer Center, Houston
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT06507878Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- MD Anderson Cancer Center, Houston
- START San Antonio, San Antonio
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT05786924Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma
- The University of Texas M. D. Anderson Cancer Center, Houston
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT07218315Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
- MD Anderson Cancer Center, Houston
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT06959511Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
- MD Anderson Cancer Center, Houston
Menerima pesertaFase 2
Usia 2 hingga 25 · Semua jenis kelamin · Diperbarui 24 Jul 2026 · NCT06458036A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- UT Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
Menerima pesertaFase 1/2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 27 Mei 2026 · NCT03093116An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy
- M D Anderson Cancer Center, Houston
Menerima pesertaFase 1Sukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Mei 2026 · NCT04589624Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- MD Anderson Cancer Center, Houston
- NEXT Oncology, San Antonio
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Mei 2026 · NCT06239194Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
- M D Anderson Cancer Center, Houston
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Apr 2026 · NCT04693377cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Elligo Health Research, Inc., Austin
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 40 ke atas · Semua jenis kelamin · Diperbarui 20 Jan 2026 · NCT05366881Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
- MD Anderson Cancer Center, Houston
Menerima pesertaFase 2
Usia 2 hingga 99 · Semua jenis kelamin · Diperbarui 14 Nov 2025 · NCT05783323Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
- University of Texas Health Science Center, San Antonio
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Semua usia · Semua jenis kelamin · Diperbarui 15 Okt 2025 · NCT03160274Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
- MD Anderson Cancer Center, Houston
Menerima pesertaFase 2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 12 Des 2024 · NCT05668962Dari ClinicalTrials.gov, data diambil 3 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.